Diffusion Pharmaceuticals Inc. Common Stock
(NASDAQ:DFFN)
Description
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company is also developing DFN-529, a phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway inhibitor. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
DFFN Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$1.0600 |
Previous Close Volume |
5480588 |